These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 12637586

  • 1. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, Yu DY, Shong M.
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [Abstract] [Full Text] [Related]

  • 2. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M.
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [Abstract] [Full Text] [Related]

  • 3. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M.
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [Abstract] [Full Text] [Related]

  • 4. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, Shong M.
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [Abstract] [Full Text] [Related]

  • 5. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
    Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M.
    Oncogene; 2004 Mar 18; 23(12):2188-96. PubMed ID: 14981541
    [Abstract] [Full Text] [Related]

  • 6. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M, De Falco V, Bai XH, Kapus A, Melillo RM, Santoro M, Liu M.
    Oncogene; 2009 Feb 19; 28(7):937-49. PubMed ID: 19060924
    [Abstract] [Full Text] [Related]

  • 7. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
    Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM.
    BMC Cancer; 2008 May 23; 8():144. PubMed ID: 18498667
    [Abstract] [Full Text] [Related]

  • 8. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA.
    Endocrinology; 2006 Feb 23; 147(2):1014-9. PubMed ID: 16254036
    [Abstract] [Full Text] [Related]

  • 9. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM.
    Cancer Res; 2005 Mar 01; 65(5):1729-37. PubMed ID: 15753368
    [Abstract] [Full Text] [Related]

  • 10. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.
    Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, Shong M.
    Mol Endocrinol; 2005 Nov 01; 19(11):2748-59. PubMed ID: 15994200
    [Abstract] [Full Text] [Related]

  • 11. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.
    Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA.
    Oncogene; 2003 Oct 09; 22(44):6830-8. PubMed ID: 14534528
    [Abstract] [Full Text] [Related]

  • 12. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.
    Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ, Sheils O.
    Mol Cancer; 2006 Dec 11; 5():70. PubMed ID: 17156473
    [Abstract] [Full Text] [Related]

  • 13. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G, Gaulier A.
    Br J Cancer; 2001 Dec 14; 85(12):1831-7. PubMed ID: 11747322
    [Abstract] [Full Text] [Related]

  • 14. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM, O'Leary JJ, Sweeney EC.
    J Pathol; 2000 Sep 14; 192(1):32-6. PubMed ID: 10951397
    [Abstract] [Full Text] [Related]

  • 15. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.
    Am J Pathol; 2004 Aug 14; 165(2):511-21. PubMed ID: 15277225
    [Abstract] [Full Text] [Related]

  • 16. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
    Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL, Fusco A, Santoro M, Melillo RM.
    Oncogene; 2004 Aug 05; 23(35):5958-67. PubMed ID: 15184868
    [Abstract] [Full Text] [Related]

  • 17. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.
    Buckwalter TL, Venkateswaran A, Lavender M, La Perle KM, Cho JY, Robinson ML, Jhiang SM.
    Oncogene; 2002 Nov 21; 21(53):8166-72. PubMed ID: 12444552
    [Abstract] [Full Text] [Related]

  • 18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 19. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
    Santoro M, Melillo RM, Fusco A.
    Eur J Endocrinol; 2006 Nov 01; 155(5):645-53. PubMed ID: 17062879
    [Abstract] [Full Text] [Related]

  • 20. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.
    J Natl Cancer Inst; 2004 Aug 18; 96(16):1231-9. PubMed ID: 15316058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.